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ENVENOMATIONS by  the  snake  Bothrops  asper  are
characterized by prominent local tissue damage (i.e.
myonecrosis),  blistering,  hemorrhage  and  edema.
Various  phospholipases  A2 and  metalloproteinases
that induce local pathological alterations have been
purified from this venom. Since these toxins induce a
conspicuous  inflammatory  response,  it  has  been
hypothesized that inflammatory mediators may con-
tribute to the local pathological alterations described.
This study evaluated the local production of cytokines
and  matrix  metalloproteinases  (MMPs)  as  a  con-
sequence  of  intramuscular  injections  of  an  Asp-49
myotoxic  phospholipase  A2 (myotoxin  III  (MT-III))
and a P-I type hemorrhagic metalloproteinase (BaP1)
isolated from B. asper venom. Both enzymes induced
prominent tissue alterations and conspicuous incre-
ments  in interleukin (IL)-1b , IL-6  and a number of
MMPs,  especially  gelatinase  MMP-9,  rapidly  after
injection. In contrast, no increments in tumor necro-
sis factor-a (TNF-a ) and interferon-g were detected.
In  agreement,  MT-III  and  BaP1  did  not  induce  the
synthesis  of  TNF-a by  resident  peritoneal  macro-
phages in vitro. Despite the conspicuous expression
of  latent  forms  of  MMPs  in  muscle,  evidenced  by
zymography, there were no increments in activated
MMP-2 and only a small increase in activated MMP-9,
as  detected  by  a  functional  enzymatic  assay.  This
suggests that MMP activity was regulated by a highly
controlled activation of latent forms and, probably,
by a concomitant synthesis of MMP inhibitors. Since
no  hemorrhage  nor  dermonecrosis  were  observed
after injection of MT-III, despite a prominent increase
in MMP expression, and since inflammatory exudate
did not enhance hemorrhage induced by BaP1, it is
suggested  that  endogenous  MMPs  released  in  the
tissue are not responsible for the dermonecrosis and
hemorrhage characteristic of B. asper envenomation.
Moreover, pretreatment of mice with the peptidomi-
metic MMP inhibitor batimastat did not reduce myo-
toxic nor edema-forming activities of MT-III, suggest-
ing that MMPs do not play a prominent role in the
pathogenesis  of  these  effects  in  this  experimental
model. It is concluded that MT-III and BaP1 induce a
local  inflammatory  response  associated  with  the
synthesis of IL-1b , IL-6 and MMPs. MMPs do not seem
to  play  a prominent  role  in  the  acute  local  patho-
logical  alterations  induced  by  these  toxins  in  this
experimental model.
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Introduction
Envenomations induced by the bites of snakes from
the family Viperidae are characterized by drastic local
tissue damage involving necrosis of muscle, blistering,
hemorrhage  and  a  prominent  inflammatory  res-
ponse, associated with edema, pain and a leukocyte
infiltrate.1–3 The pathogenesis of these alterations is
rather complex, involving both the direct action of
tissue-damaging toxins present in the venom and the
participation  of  endogenous  mediators  that  might
contribute to such alterations. However, the precise
role of each of these elements in venom-induced local
effects has not been fully elucidated.
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snake in Central America, where it inflicts more than
50%  of  snakebites.4 Its  venom  induces  prominent
local tissue damage.1,5Acute muscle damage is caused
by  a  group  of  highly  basic  phospholipases A2 and
phospholipase A2 homologs that bind to and disrupt
skeletal muscle cell plasma membrane, promoting a
calcium  influx  that  culminates  in  irreversible  cell
damage.5,6 Hemorrhage is induced by the action of
zinc-dependent  metalloproteinases  that  hydrolyze
proteins of the basement membrane of capillaries. As
a  consequence,  endothelial cells  are  affected,  with
disruption of the capillary wall and extravasation.7–10
Metalloproteinases are also responsible for blistering,
probably by degrading basement membrane compo-
nents at the dermal–epidermal junction.11
Besides the direct action of venom phospholipases
A2and  metalloproteinases,  B.  asper envenomations
are also characterized by the synthesis and release of
a  number  of  endogenous  mediators  that  promote
edema and pain.12–14 However, little is known on the
local synthesis of cytokines and matrix metalloprotei-
nases (MMPs) in  B.  asper envenomations. Previous
investigations have documented elevated serum lev-
els of some cytokines after experimental injections of
various Bothrops sp. venoms,15–17 and increments in
MMPs  in  skin  and  exudates  after  intramuscular
injection  of  B.  asper P-I  type  hemorrhagic  metal-
loproteinase BaP1 were described.11 Furthermore, it
was observed that venom metalloproteinases are able
to release tumor necrosis factor-a (TNF-a)  from  its
recombinant  precursor  in  vitro.18 Cytokines  and
MMPs are important mediators of tissue damage and
inflammation in a variety of pathologies,19,20 and they
may  play  a role in  venom-induced local alterations,
enhancing  the  tissue  damage  initiated  by  venom
components,  a  hypothesis  that  needs  to  be
addressed.
The  aim  of  the  present  work  was  to  determine
whether cytokine and MMP levels increase in muscle
tissue injected with two tissue-damaging toxins from
B.  asper venom,  myotoxic  phospholipase A2 myo-
toxin III (MT-III) and hemorrhagic metalloproteinase
BaP1. Furthermore, the possible role of MMPs in the
pathogenesis of acute local tissue damage was investi-
gated in this experimental model.
Materials and methods
Toxins
MT-III and metalloproteinase BaP1 were isolated from a
venom  pool  obtained  from  more  than  40  adult
specimens of B. asper collected in Costa Rica and kept
at the Serpentarium of Instituto Clodomiro Picado. MT-
III was isolated by ion-exchange chromatography on
CM-Sephadex C-25,21,22whereas BaP1 was purified by
ion-exchange chromatography on CM-Sephadex C-25,
gel filtration on Sephacryl S-200 and affinity chroma-
tography  on Affi-gel  Blue.11,23 Homogeneity  of  the
enzymes was demonstrated by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis under reduc-
ing conditions.24
Determination of increments in MMPs
Groups of four Swiss mice (18–20g) were injected
intramuscularly  (i.m.),  in  the  right  gastrocnemius,
with 60mg of either MT-III or BaP1, dissolved in 60ml
of  sterile,  endotoxin-free  saline  solution  (0.15M
NaCl).  All  animal  experiments  in  this  study  were
approved  by  the Animal  Ethical  Committee  of  the
University of Costa Rica. Control mice received 60ml
of  sterile  saline  solution  alone.  At  various  time
intervals, mice were killed by CO2 inhalation, and the
injected  gastrocnemius  were  dissected  out  and
homogenized in 2.0ml of endotoxin-free saline solu-
tion  using  a  PT  10/35  homogenizer  (Brinkmann
Instruments Co., New York,  USA).  Muscle  homoge-
nates were centrifuged at 6000 ´ g for 5min and the
supernatants  collected,  stored  at  –70°C  and  used
within the following week. The protein concentration
of all samples was assessed according to Spector25 in
order to load the same amount of protein in the gels.
Metalloproteinase activity was visualized by  zymog-
raphy, according to the procedure of Herron et al.,26
with the modifications described by Rucavado et al.11
Briefly, electrophoreses were performed at 100V in a
Mini-Protean cell (Bio-Rad, CA, USA), using a 5–20%
gradient  SDS-polyacrylamide  gel  containing Type  A
gelatin  (Sigma  Chemical  Co,  St  Louis,  MO,  USA).
Molecular  weight  markers  were  included.  After  a
washing step with 2.5% Triton X-100 with shaking for
30min,  gels  were  incubated  at  37°C  for  18h  in
50 mM Tris–HCl  (pH  8.0)  buffer,  containing  5 mM
CaCl2 and 20mg/dl of sodium azide. Gels were then
stained  with  0.5%  Coomassie Blue  R-250  in  acetic
acid:isopropyl  alcohol:water  (1:3:6)  and  destained
with distilled water. Gels run under identical condi-
tions  were  incubated  in  the  presence  of  20 mM
ethylenediamine  tetraacetic  acid  (EDTA)  to  inhibit
metalloproteinases.
Since the zymography assay described detects both
latent  and  active  MMPs,  as  well  as  those  forming
complexes with TIMPs, additional experiments were
performed to estimate the concentration of latent and
active MMPs in muscle homogenates. Active MMP-2
and MMP-9 were quantitated by the functional assay
system  Biotrak  (codes  2630  and  2631;  Amersham
Pharmacia  Biotech,  UK).  In  conditions  where
p-aminophenylmercuric acetate (APMA) is not added
to the enzyme, this assay detects only active MMPs.
Addition of APMA allows detection of both latent and
active forms. Homogenate samples, standardized by
protein  concentration,25 were  added to  microplate
wells  in  which  either  anti-MMP-2  or  anti-MMP-9
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incubation at 4°C and a washing step, the pro-enzyme
form of a detection enzyme was added, together with
its substrate, and the plates were incubated at 37°C.
Active MMPs cleave this pro-enzyme, activating it to
hydrolyze its substrate with the formation of a colored
product. Absorbances at 405nm were recorded in a
Multiskan microplate reader and enzymatic activitiy
was  determined  on  the  basis  of  a  standard  curve
prepared with purified MMP-2 and MMP-9.
Quantification of cytokine levels
For quantification of cytokine levels in muscle, the
same homogenization protocol already described was
followed.  TNF-a,  interleukin  (IL)-1b,  interferon-g
(IFN-g) and IL-6 were quantitated by enzyme-immu-
noassays (Quantikine™M; R & D Systems, MN, USA)
following the manufacturer’s instructions. TNF-a was
also  quantitated  by  a  cytotoxic  assay  using  the
fibroblast  cell  line  L-929,27 with  the  modifications
described by Petricevich et al.17 Briefly, monolayers
of  L-929 cells were seeded in  microtiter plates and
incubated  in  a  humidified  air  atmosphere with  5%
CO2 at  37°C  for  18h.  Then,  samples  of  muscle
homogenates in RPMI-1640, containing 1.0mg/ml of
actinomycin D, were added. After incubation for 18h
at 37°C, supernatants were removed and viable cells
were assessed after fixation and staining with crystal
violet  (0.2%  in  20%  methanol).  Negative  controls
included  cells  incubated  with  RPMI  medium.  A
standard curve was prepared with known concentra-
tions of recombinant TNF-a.
Effects of BaP1 on macrophages in vitro
Resident,  non-elicited  macrophages  were  collected
from  anesthetized  Swiss  mice  by  lavage  of  the
peritoneal cavity with  sterile 0.15M  NaCl solution.
Cells were counted in a hemocytometer, centrifuged
and  pelleted.  Macrophages  were  resuspended  in
RPMI medium and applied to plates (1.5 ´ 105cells/
well) and incubated with MT-III or BaP1 (6.25, 12.5
and 25.0mg/ml) for 60min at 37°C under a 95% air,
5%  CO2 atmosphere.  In  some  experiments,  super-
natants  of  macrophage  cultures  were  assessed  for
the  presence  of TNF-a by  the  cytotoxic  assay  on
L929 cells already described. An additional step was
introduced  in  some  experiments  to  increase  the
sensitivity of the assay. After incubation with toxins,
macrophages  were  harvested  and  2  ´ 104 cells,
suspended in  RPMI  medium,  were  directly  applied
on monolayers of L929 cells. After 24h of incubation
at 37°C, the viability of L929  cells  was assessed as
already described. Recombinant TNF-a and anti-TNF-
a antibodies were used in  some controls to assure
that the cytotoxic effect was indeed caused by this
cytokine.
Histological studies
To determine whether treatment with MT-III or BaP1
induces skin lesions, mice were injected with 60mg
of these toxins i.m. in the gastrocnemius, as descri-
bed, and were killed at 1 or 3h. The skin overlying the
injected area was dissected out, cut into small pieces
and  fixed  in  Karnovsky’s  fixative  (2.5%  glutaralde-
hyde,  2%  paraformaldehyde  in  0.1M  phosphate
buffer; pH 7.2). Postfixation was performed with 1%
osmium  tetroxide. Afterwards,  samples  were  dehy-
drated in ethanol and embedded in Spurr resin.7 One
micrometer  sections  were  cut  and  stained  with
toluidine blue for histological observation.
Inhibition by the peptidomimetic hydroxamate
batimastat
To determine whether MMPs synthesized after MT-III
injection contribute to  muscle  damage and  edema,
mice  were  pretreated with  an  intraperitoneal (i.p.)
injection of the peptidomimetic inhibitor batimastat
(BB-94; British Biotech Pharmaceuticals Ltd., Oxford,
UK). Batimastat suspension was prepared by sonica-
tion in phosphate-buffered saline solution (PBS) (pH
7.2), containing 0.01% Tween 80 and injected intra-
peritoneally  at  a  dose  of  30mg/kg. This  dose  was
selected since it has been used in  previous studies
dealing with the effect of this inhibitor in experimental
cancer models,28 in which a systemic concentration
above the IC50 values for MMPs was reached. Three
hours  after  batimastat  administration,  mice  were
injected  with  MT-III  either  i.m.  (50mg),  in  the
gastrocnemius,  or  subcutaneously  (20mg),  in  the
footpad,  for  the  assessment  of  myonecrosis  and
footpad  edema,  respectively.11,29 Myotoxicity  was
evaluated 3h after MT-III injection by determining the
plasma  creatine  kinase  (CK)  activity.30 Edema  was
evaluated  by  measuring  the  increase  in  footpad
thickness at various time intervals after toxin injection
with the aid of a low-pressure spring caliper.15,29
Potentiation of BaP1-induced hemorrhage and
dermonecrosis by inflammatory exudate
Inflammatory exudate was collected from  mice 3h
after  i.m.  injection  of  60mg  of  MT-III  in  the  right
gastrocnemius.  Animals  were  killed  and  a  small
incision was made in the skin overlying the injected
muscle.  Exudate  was  collected  into  heparinized
capillary tubes and centrifuged at 2000 ´ g for 5min.
For studying the possible effect of MMPs present in
inflammatory exudate on the hemorrhagic and dermo-
necrotic activities of BaP1, groups of five mice were
injected intradermally, in the abdominal region, with
either BaP1 plus PBS, BaP1 plus exudate, or exudate
plus PBS. Animals were killed after either 2 or 72h for
quantification of hemorrhagic and necrotizing lesions,
respectively.31,32 Hemorrhagic  and  necrotic  areas
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hemorrhagic areas were cut and placed into 2ml of
distilled water overnight for elution of hemoglobin.
Tubes  were  centrifuged  and  the  absorbances  of
supernatants  recorded  at  540nm  as  a  quantitative
assessment of hemoglobin concentration.
Statistical analysis
The significance of the differences between the mean
values of two experimental groups was determined
by  the  Student’s  t-test,  using  p <  0.05  to  establish
significance.
Results
Studies on MMPs and cytokines in muscle
Samples of muscle homogenates obtained from mice
injected  with  saline  solution  showed  two  main
proteolytic bands of 100 and 60kDa when analyzed
by zymography (Fig. 1). A conspicuous increment in
the intensity  of the 100kDa band was observed in
samples  obtained  1  and  6h  after  MT-III  and  BaP1
injections (Fig. 1). In addition, bands of 270, 230, 135,
115,  74,  65  and  57kDa were  also  detected. When
incubations  were  carried  out  in  the  presence  of
EDTA, proteolytic activity was abrogated. There were
no qualitative differences in the zymographic pattern
between samples obtained from mice injected with
MT-III and BaP1.
Enzymatic  activity  of  MMP-2  and  MMP-9  was
quantified  in  muscle  homogenates  by  a  functional
assay that includes an antibody-binding step, followed
by  a  quantitative  enzymatic  determination.  When
compared with homogenates from mice injected with
saline  solution,  no  increments  in  either  latent  or
activated forms of MMP-2 were detected. In contrast,
both  toxins  induced  increments  in  MMP-9  activity.
When  only  the  active  form  of  the  enzyme  was
detected, activity was: BaP1, 1h, 17 ± 2ng/g tissue;
BaP1, 6h, 8 ± 3ng/g; MT-III, 1h, 17 ± 2ng/g; MT-III,
6h, activity below the detection limit  of  the assay.
When both latent and active forms were quantified
(i.e. when APMA was included in the assay), activity
increased significantly: BaP1, 1h, 180 ± 5ng/g tissue;
BaP1, 6h, 78 ± 28ng/g; MT-III, 1h, 789 ± 181ng/g; MT-
III, 6h, 65 ± 0.2ng/g. Thus, most of the expressed
MMP-9 was in the latent form at these time intervals.
A prominent increment in muscle  levels  of IL-1b
and IL-6 was observed early after injection of MT-III
and BaP1, higher levels being induced by myotoxin
administration (Fig. 2). Maximum levels were attained
between 3 and 6h, decreasing afterwards. In contrast,
no  evidence  of TNF-a nor  IFN-g increments  were
detected  in  muscle  homogenates  by  the  enzyme
A. Rucavado et al.
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FIG.  1.  Zymograms  of  muscle  homogenates  from  mice
injected i.m. with 60mg of MT-III or BaP1. Gelatinase activity
was assessed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (5–20% acrylamide gradient) containing 1%
type A  gelatin. Muscle homogenates after injection of: (1)
BaP1, 1h; (2) BaP1, 6h; (3) MT-III, 1h; (4) MT-III, 6h; (5) saline.
Molecular weight markers are depicted to the left.
FIG. 2. Increments of IL-1b and IL-6 in muscle homogenates
after i.m. injection of 60mg of MT-III or BaP1, dissolved in
60ml of saline solution. Control mice received saline solution
alone. Mice were injected in the right gastrocnemius and, at
various  time  intervals,  they  were  killed  and  the  injected
muscle was excised, weighed and homogenized in 2.0ml of
saline  solution.  After  centrifugation,  cytokine  levels  were
quantitated  by  enzyme-linked  immunosorbent  assay  (see
Materials and methods). Results are presented as mean ±
standard deviation (n = 4).immunoassay utilized. In these cases, cytokine con-
centration did not differ significantly  from those of
saline-injected muscle and were below the detection
limit of the assay. In agreement with this, TNF-a was
not detected in muscle homogenates by the cytotoxic
assay on fibroblasts L929.
Effect of BaP1 on TNF-a production by
macrophages in vitro
Neither MT-III nor BaP1 induced the synthesis of TNF-
a by resident non-elicited peritoneal macrophages on
incubation in vitro for 60min, as evidenced by lack of
cytotoxicity of supernatants on L929 cells (results not
shown).  To  increase  the  sensitivity  of  the  assay,
macrophages  that  had  been  incubated  with  toxins
were  harvested and  directly  applied  to  cultures  of
L929 cells. Again, negative results were obtained at
the doses tested.
Histological studies
Pathological alterations induced by B. asper myotox-
ins and BaP1 in muscle have been previously descri-
bed in detail.6,10 In the present study, we investigated
the alterations induced by these toxins in the skin.
Control mice injected with saline solution showed a
normal morphology, with the characteristic structure
of  epidermis,  dermis  and  hypodermis.  In  contrast,
samples  from  mice  injected  with  BaP1  showed
prominent  hemorrhage  and  inflammation  in  the
hypodermis and dermis, together with the formation
of  blisters,  characterized by  the  separation  of  epi-
dermis  from  the  underlying  dermis,  in  agreement
with previous observations11 (Fig. 3A). Skin samples
from mice injected with MT-III showed only a mild
inflammatory reaction in the dermis. No evidence of
blisters were observed (Fig. 3B), although there was
necrosis  of  the  panniculus  carnosus  muscle  (not
shown), indicating that the toxin reached the skin.
Inhibition by batimastat and effect of exudate
on BaP1-induced hemorrhage
Administration  of  batimastat  by  the  i.p.  route  3h
before MT-III injection did not decrease the extent of
edema induced by this myotoxin (Table 1). Regarding
myotoxicity, plasma CK levels of mice injected with
MT-III alone were 4051 ± 268U/l, CK levels of MT-III-
injected mice that had been pretreated with batima-
stat were  3880  ±  297U/l,  and  CK  levels  of  MT-III-
injected  mice  pretreated  with  batimastat  and
receiving an additional local injection of  batimastat
were  3524  ±  399U/l.  None  of  these  treatments
promoted a significant reduction of myotoxicity (p >
0.05). Inflammatory exudate collected 3h after MT-III
injection, having a protein concentration of  4.00 ±
0.24g/dl, did not increase nor reduce the extent of
hemorrhage  induced  by  intradermal  injections  of
BaP1  (Table  2).  Inflammatory  exudate  itself  lacked
hemorrhagic activity in these assays. Moreover, mice
receiving  an  intradermal  injection  of  BaP1  alone
presented a necrotic skin lesion of 3.73 ± 0.15mm (n
= 3) 3 days after injection. When BaP1 was co-injected
with exudate, the diameter of the necrotic lesion was
3.57 ± 0.15mm (p > 0.05 when compared with BaP1
alone),  exudate  alone  being  devoid  of  necrotizing
effect.
Discussion
A conspicuous increase in IL-1b and IL-6, as well as a
prominent  increment  in  the  expression  of  MMP-9,
were observed in gastrocnemius muscle injected with
MT-III  and  metalloproteinase  BaP1.  Local  tissue
pathology induced by B. asper venom, and probably
by  other crotaline snake venoms as well,  is mainly
Cytokines and MMPs in snake envenomation
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FIG.  3.  Light  micrographs  of  sections  of  skin  from  mice
injected i.m. in the gastrocnemius with 60mg of either BaP1
(A)  or  MT-III  (B).  Tissue  samples  were  obtained  3h  after
injection,  processed  and  embedded  in  Spurr  resin.  Thick
(1mm) sections were stained with toluidine blue. Notice the
presence of hemorrhage in the dermis and the formation of
a blister (Bli) in mice injected with BaP1, whereas no evident
pathological  alterations  in  dermis  and  epidermis  were
observed after injection of MT-III.characterized by a direct muscle damage induced by
phospholipases A2, and by blistering and microvessel
disruption  and  bleeding  induced  by  metalloprotei-
nases.5,8,11,33 Interestingly,  despite the  different  tar-
gets and mode of action of these toxins, MT-III and
BaP1 induced a qualitatively similar pattern of cyto-
kine and MMP expression in injected muscle. Thus, it
is  likely  that  muscle  tissue  responds  in  a  rather
stereotyped fashion to locally acting agents of differ-
ent  nature  present  in  snake venoms.  Cytokine and
MMP  increments  are  likely  to  be  related  since  a
variety  of  cytokines,  including  TNF-a and  IL-1b,
induce MMP expression.20,34
Prominent increments of IL-1b and IL-6 occurred,
whereas  no  elevations  of  TNF-a and  IFN-g were
detected. In the case of TNF-a, this observation was
corroborated using both an enzyme immunoassay and
a cytotoxicity assay. This lack of correlation between
IL-1b and TNF-a increments might be due to the fact
that the former is produced by a number of different
cells  types,  such  as  macrophages,  endothelial cells
and  other  cell  types,35,36 whereas TNF-a is  mainly
produced by macrophages. Resident macrophages are
present in skeletal muscle,37 but they are not elicited
under normal conditions. Thus, when MT-III and BaP1
are injected, these resident macrophages do not seem
to synthesize levels of TNF-a that could be detected
by  the  assays  performed.  In  agreement  with  this
contention, TNF-a was  not  detected in  cultures  of
non-elicited  resident  peritoneal  macrophages  incu-
bated with these toxins. In contrast with our observa-
tions, Clissa et al.38 described the production of TNF-
a by  peritoneal  macrophages  incubated  with
jararhagin,  a  P-III  hemorrhagic  metalloproteinase
from B. jararaca venom. This apparent discrepancy
may be related to the type of macrophage used, since
Clissa  et  al.38 worked  with  thioglycollate-elicited
macrophages,  whereas  our  experiments  were  per-
formed with resident, non-elicited cells. It would be
relevant  to  compare  the  effect  of  tissue-damaging
toxins on cytokine production by resident, elicited
and activated macrophages.
Increments  in  serum  levels  of  IL-6  have  been
observed in mice injected with B. asper and B. atrox
venoms.15–17 IL-6 is  a  major mediator of inflamma-
tion,39 inducing the synthesis of acute-phase proteins
in  the  liver.40 In  addition,  IL-6  induces  myoblast
proliferation  in  culture,41 suggesting  that  the
observed increments in this cytokine may influence
skeletal  muscle  regeneration  after  snake  venom-
induced myonecrosis. IL-1b plays a number of roles in
inflammation,  inducing  the  expression  of  adhesion
molecules,42and the release of leukocyte chemotactic
factors,43 besides altering the functional properties of
endothelial cells.35 IL-1b promotes inflammation after
skeletal muscle injury.44 In addition, these cytokines
induce MMP expression34 and probably contribute to
the synthesis of MMPs observed in our experimental
models,  since  early  increments  in  these  cytokines
correlated with the expression of MMPs. Increments
in  the serum  levels  of  a number  of  cytokines have
been described in patients after snakebite envenoma-
tions.45,46Thus, cytokines may play a relevant role in
the  pathophysiology  of  these  envenomations  in
humans.
MMPs constitute a group of more than 20 enzymes,
with  the  common  ability  to  degrade  extracellular
matrix  components,  that  play  essential  roles  in
embryonic development, reproduction, tissue remod-
eling  and  inflammation.19,20 These  enzymes  are
usually  not  constitutively  present  in  cells,  being
synthesized as prepro-enzymes and secreted as inac-
tive  pro-enzymes  by  a  variety  of  cell  types  in
inflammatory processes.19,47 However, a constitutive
expression of MMP-2 has been described for mouse
skeletal muscle,48in agreement with our observations
in control muscle. Zymography results indicate that a
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Table 1. Lack of inhibition of edema-forming activity of MT-III
by pretreatment with the MMP inhibitor batimastat
Time
(min)
Treatment*
Control Batimastat
0† 1.72 ± 0.15‡ 1.69 ± 0.09
15 3.18 ± 0.08 3.15 ± 0.09
60 2.94 ± 0.09 2.99 ± 0.13
180 2.69 ± 0.07 2.76 ± 0.12
*Mice received an i.p. injection of batimastat (30mg/kg in PBS-0.01 %
Tween), 3h afterwards they were injected subcutaneously (s.c.) in the
right  footpad  with  20mg  of  MT-III  in  50ml  of  PBS.  Control  mice
received an i.p. injection of PBS–Tween followed by as.c. injection of
MT-III as described. Edema is expressed as footpad thickness (mm).
†0 represents footpad thickness immediately before injection of MT-III.
‡Mean ± standard deviation (n = 4). No significant differences were
observed at any time interval (p > 0.05).
Table 2. Effect of the inflammatory exudate, obtained from
mice  injected  with  MT-III,  on  the  hemorrhagic  activity  of
metalloproteinase BaP1*
Treatment Diameter of
hemorrhagic lesions
Absorbance
at 540nm
PBS 0 0.008 ± 0.002†
PBS + exudate 0 0.009 ± 0.002
BaP1 + PBS 14.5 ± 2.3mm 0.327 ± 0.165
BaP1 + exudate 13.8 ± 1.9mm 0.358 ± 0.117
*Groups  of  mice  were  injected  i.m.  with  60mg  of  MT-III  and
inflammatory exudate  was  collected  from  underneath  the  skin  3h
after injection. Then, groups of four mice were injected intradermally
with either PBS (90ml), PBS (50ml) + exudate (40ml), BaP1 (40mg/50
ml) + PBS (40ml), or BaP1 (40mg/50 ml) + exudate (40ml). Hemorrhagic
activity was assessed 2h after injection by measuring the diameter of
the hemorrhagic  spots.  Then, skin  samples  containing  the  hemor-
rhagic areas were dissected out and placed into 2ml of distilled water
overnight for elution of hemoglobin. Tubes were centrifuged and the
absorbances  of supernatants  recorded  at 540nm as a  quantitative
assessment of hemoglobin concentration.
†Mean ±  standard  deviation  (n =  4).  The differences  between  the
mean values of mice receiving BaP1 + PBS and those receiving BaP1
+ exudate were not significant (p > 0.05).number of MMPs, especially MMP-9, are expressed in
muscle injected with MT-III and BaP1. Bands of 60 and
100kDa  observed  in  zymography  probably  corre-
spond  to  the  latent  forms  of  MMP-2  and  MMP-9,
respectively,  as  these  molecular  masses  have  been
described for these enzymes in mice.48 High activity
was  detected  in  muscle  homogenates  when  both
latent and active MMP-9 were quantitated, whereas
activity  was  greatly  reduced  when  only  the  active
form was quantitated by a specific enzymatic assay.
This  strengthens  the  conclusion  that  most  of  the
increment in MMP-9 corresponds to the latent form of
the enzyme. MMP-2 and MMP-9 have been reported to
increase in a variety of pathologies, such as myonecro-
sis,48 chronic  inflammation,49 meningitis,50 intra-
cerebral  hemorrhage  and  ischemia,51,52 and  acute
lung injury,53 among others. In addition to these two
MMPs,  other  gelatinolytic  bands  were  observed  in
muscle  homogenates  and  exudates  in  our  experi-
mental model, which probably correspond to other
members of the MMP family. We also detected two
bands  of  270  and  230kDa,  which  might  represent
MMP  aggregates.54 Although  the  cellular  source  of
MMPs was not addressed in this study, it is suggested
that resident macrophages, fibroblasts and endothelial
cells constitute the main sources of MMPs during the
first hours after injection of these toxins.34,53,55,56
In  the  physiological  processes  in  which  MMPs
participate,  the  balance  between  MMP  expression,
activation and inhibition by TIMPs and other inhibitors
is finely regulated.20 On the contrary, exaggerated or
unregulated expression of MMPs may lead to uncon-
trolled  extracellular  matrix  degradation  and  tissue
damage,  as  occurs  in  chronic  wounds.49 Thus,  the
question was raised in this study as to whether the
observed increment in MMP expression contributes to
the acute local tissue damage characteristic of B. asper
envenomation.  Several  lines  of  evidence  strongly
suggest that MMPs do not contribute significantly to
the acute tissue damage induced by MT-III and BaP1
during  the  first  6h  after  injection  of  the  toxins.
Pretreatment with batimastat, a potent MMP inhibitor
having broad specificity, did not reduce the extent of
edema and myonecrosis induced by MT-III. Moreover,
MT-III injection did not induce local hemorrhage nor
blistering, despite the conspicuous increase in MMP-9
expression. Thus, in the case of BaP1, it is suggested
that hemorrhage and blister formation are mainly due
to the direct action of this venom metalloproteinase at
the basement membrane of capillary vessels and the
epidermis. This  conclusion  is  strengthened  by  the
observation that concomitant injection of BaP1 and
inflammatory exudate containing MMPs induced sim-
ilar  hemorrhagic  and  dermonecrotic  lesions  when
compared  with  mice  injected  with  BaP1  alone.  In
addition,  local  injection  of  inflammatory  exudates
obtained  from  MT-III-injected  mice  did  not  induce
dermonecrosis nor hemorrhage.
As  evidenced  by  zymography  and  by  a  specific
enzymatic assay, MMPs in muscle homogenates corre-
sponded predominantly to the latent forms, therefore
lacking  activity  under  non-denaturing  conditions,
such as those operating in vivo. Thus, the apparent
lack of pathological effects of MMPs in  this model
might be associated with the very low concentration
of the active forms of these enzymes in the tissue. It is
likely  that MMP  activity  is  finely  controlled  in  our
experimental  conditions  by  keeping  most  of  the
enzymes  in  their  latent  form  and,  probably,  by  a
parallel expression of TIMPs. As a consequence, free
metalloproteinase activity  is  maintained under  con-
trol.  It  has  been  observed  that  the  acute  wound
microenvironment,  such  as  that  of  our  model,  is
characterized by a controlled balance of MMPs and
their  inhibitors,  whereas  in  chronic  wounds  this
balance is disrupted, with the concomitant increment
in  MMP  free  activity  associated  with  prominent
extracellular matrix degradation and pathology.49,57 It
is  therefore  likely  that  MMP  expression  in  our
experimental model is a regulated event that does not
seem to play a prominent role in the acute local tissue
damage induced by these toxins within the first hours
after injection. Instead, MMPs probably participate in
the  inflammatory  response,  by  remodeling  extrac-
ellular matrix and promoting events associated with
inflammatory cell influx, release of matrix-embedded
growth factors and onset of tissue regeneration. The
role  of  MMPs  in  the  inflammatory  and  reparative
processes taking place after the onset of acute local
tissue  damage  induced  by  snake  venom  toxins
remains to be investigated.
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